Sayeh Dowlatshahi is a Ph.D. candidate at the Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana. She received her bachelor’s degree in chemical engineering and her master’s in biomedical engineering from Sharif University of Technology, Tehran, Iran. Her research interests include point-of-care cancer diagnostics and microfluidic biosensor design and development. Working under Prof. Jacqueline Linnes at Purdue, Sayeh is developing a paper-based assay detecting topoisomerase II alpha for sensitive and specific identification of high-grade premalignant lesions of the cervix. She plans to combine multiplex protein detection with machine learning for more accurate and reliable disease screening. Sayeh also has extensive experience quantifying proteins in cervical cells and optimizing cervical swab sampling. Upon obtaining her doctoral degree, she plans on staying in academia to conduct cutting-edge research and develop robust cancer screening assays for low-resource settings, contributing to alleviating the burdens of this malignancy globally.
Sayeh Dowlatshahi is a Ph.D. candidate at the Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana. She received her bachelor’s degree in chemical engineering and her master’s in biomedical engineering from Sharif University of Technology, Tehran, Iran. Her research interests include point-of-care cancer diagnostics and microfluidic biosensor design and development. Working under Prof. Jacqueline Linnes at Purdue, Sayeh is developing a paper-based assay detecting topoisomerase II alpha for sensitive and specific identification of high-grade premalignant lesions of the cervix. She plans to combine multiplex protein detection with machine learning for more accurate and reliable disease screening. Sayeh also has extensive experience quantifying proteins in cervical cells and optimizing cervical swab sampling. Upon obtaining her doctoral degree, she plans on staying in academia to conduct cutting-edge research and develop robust cancer screening assays for low-resource settings, contributing to alleviating the burdens of this malignancy globally.